Sort   by:  
 Page size 
UnknownSmall-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.
Not available
S-EPMC10711013 | biostudies-literature
UnknownMethylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Not available
S-EPMC6162272 | biostudies-literature
UnknownTiming of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer.
Not available
S-EPMC11258338 | biostudies-literature
UnknownPaclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer.
Not available
S-EPMC4015028 | biostudies-literature
UnknownBRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Not available
S-EPMC11299415 | biostudies-literature
UnknownHigh levels of genomic aberrations in serous ovarian cancers are associated with better survival.
Not available
S-EPMC3553118 | biostudies-literature
UnknownMyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
Not available
S-EPMC5870793 | biostudies-literature
UnknownPrognostic gene expression signature for high-grade serous ovarian cancer.
Not available
S-EPMC7484370 | biostudies-literature
UnknownBreast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2.
Not available
S-EPMC3387216 | biostudies-literature
Sort   by:  
 Page size